Role for extracellular signal-responsive kinase-1 and-2 in retinal angiogenesis

被引:71
作者
Bullard, LE [1 ]
Qi, X [1 ]
Penn, JS [1 ]
机构
[1] Vanderbilt Univ, Sch Med, Dept Ophthalmol & Visual Sci, Nashville, TN 37232 USA
关键词
D O I
10.1167/iovs.01-1193
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE. Vascular endothelial growth factor (VEGF) is a potent mitogen for micro- and macrovascular endothelial cells (ECs). Evidence points to a possible role for two mitogen-activated protein (MAP) kinases, the extraceLlular-signal responsive kinases (ERK)-1 and -2, in VEGF signaling in ECs. This study was undertaken to begin to define the precise role of MAP kinases in VEGF signal transduction related to angiogenesis. METHODS. Bovine retinal microvascular endothelial cells (BRMECs) and a well-established rat model of retinopathy of prematurity (ROP) were used to investigate the role of ERK-1/2 in EC proliferation and tube formation and in retinal angiogenesis in vivo. RESULTS. Administration of VEGF to BRMEC cultures increased ERK-1/2 phosphorylation, cell proliferation, and tube formation in a dose-dependent manner. Phosphorylation of retinal ERK-1/2 also was increased in the ROP model. An inhibitor of ERK, AG126, and an inhibitor of ERK kinase (MEK), PD98059, exhibited a dose-dependent reduction of ERK phosphorylation and EC, proliferation, but not tube formation, in VEGF-stimulated BRMECs. In the ROP model, intravitreous injection of 10 muM AG126 or PD98059 reduced the retinal neovascular area by 71% and 48%, respectfully. No effect was seen on intraretinal blood vessel growth. CONCLUSIONS. These experiments point to a critical role for ERK and MEK in proliferation of ECs, but not in tube formation. Furthermore, inhibition of either of these two signal intermediates can significantly retard retinal neovascularization. This suggests that the MAPK pathway may provide rational targets for therapeutic intervention in ocular and other diseases with an angiogenic component.
引用
收藏
页码:1722 / 1731
页数:10
相关论文
共 74 条
  • [1] VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS
    AIELLO, LP
    AVERY, RL
    ARRIGG, PG
    KEYT, BA
    JAMPEL, HD
    SHAH, ST
    PASQUALE, LR
    THIEME, H
    IWAMOTO, MA
    PARK, JE
    NGUYEN, HV
    AIELLO, LM
    FERRARA, N
    KING, GL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) : 1480 - 1487
  • [2] ALESSI DR, 1995, J BIOL CHEM, V270, P489
  • [3] Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker
    Armstrong, D
    Augustin, AJ
    Spengler, R
    Al-Jada, A
    Nickola, T
    Grus, F
    Koch, F
    [J]. OPHTHALMOLOGICA, 1998, 212 (06) : 410 - 414
  • [4] Barleon B, 1997, J BIOL CHEM, V272, P10382
  • [5] BROWN LF, 1993, AM J PATHOL, V143, P1255
  • [6] BROWN LF, 1993, CANCER RES, V53, P4727
  • [7] INCREASED EXPRESSION OF VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) IN BULLOUS PEMPHIGOID, DERMATITIS-HERPETIFORMIS, AND ERYTHEMA MULTIFORME
    BROWN, LF
    HARRIST, TJ
    YEO, KT
    STAHLEBACKDAHL, M
    JACKMAN, RW
    BERSE, B
    TOGNAZZI, K
    DVORAK, HF
    DETMAR, M
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1995, 104 (05) : 744 - 749
  • [8] BROWN LF, 1995, J IMMUNOL, V154, P2801
  • [9] In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor vascular endothelial growth factor
    Cao, YH
    Linden, P
    Shima, D
    Browne, F
    Folkman, J
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (11) : 2507 - 2511
  • [10] THE FMS-LIKE TYROSINE KINASE, A RECEPTOR FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR
    DEVRIES, C
    ESCOBEDO, JA
    UENO, H
    HOUCK, K
    FERRARA, N
    WILLIAMS, LT
    [J]. SCIENCE, 1992, 255 (5047) : 989 - 991